Join Growin Stock Community!

Incannex healthcare limitedIXHL.US Overview

US StockHealthcare
(No presentation for IXHL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IXHL AI Insights

IXHL Overall Performance

IXHL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IXHL Recent Performance

-3.81%

Incannex healthcare limited

0.05%

Avg of Sector

-0.31%

S&P500

IXHL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IXHL Key Information

IXHL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IXHL Profile

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Price of IXHL

IXHL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IXHL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7764.11
PB Ratio
0.82
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-398933.33%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7764.11
PB Ratio
0.82
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-398933.33%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IXHL's latest earnings report released?

    The most recent financial report for Incannex healthcare limited (IXHL) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IXHL's short-term business performance and financial health. For the latest updates on IXHL's earnings releases, visit this page regularly.

  • How is IXHL's revenue growth?

    In the latest financial report, Incannex healthcare limited (IXHL) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IXHL have?

    As of the end of the reporting period, Incannex healthcare limited (IXHL) had total debt of 163K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IXHL have?

    At the end of the period, Incannex healthcare limited (IXHL) held Total Cash and Cash Equivalents of 69.19M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IXHL's EPS continuing to grow?

    According to the past four quarterly reports, Incannex healthcare limited (IXHL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IXHL?

    Incannex healthcare limited (IXHL)'s Free Cash Flow (FCF) for the period is -4.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 18.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.